Quantcast
Last updated on April 16, 2014 at 4:43 EDT

Latest NEUVENGE Stories

2013-10-30 23:27:16

Personalized immunotherapy vaccine developed by Perseus PCI offers breakthrough, non-toxic treatment for cancer patients that uses the body's own cells to attack tumors and turn off the engine of cancer inside the body. Austin, TX (PRWEB) October 30, 2013 Despite billions of dollars spent, thousands of clinical trials conducted and hundreds of new pharmaceutical drugs launched, the 50+ year war on cancer has resulted in few victories. Pioneering biomedical scientists at Perseus PCI...

2013-03-13 08:34:33

SEATTLE, March 13, 2013 /PRNewswire/ -- TapImmune Inc. ("TapImmune" or the "Company") (OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and gene-based vaccine technologies, announced today that the Company will present at the Florida Road Show Conference in Boca Raton, Florida on Thursday, March 14, 2013. This conference, hosted by Corporate Roadshow and Undiscovered Equities, will feature presentations by CEOs and CFOs of promising emerging growth companies...

2013-01-22 08:27:30

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488. This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of breast...

2013-01-09 08:27:41

SEATTLE, Jan. 9, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and colleagues...